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Abstract
Background: Brominated flame retardants (BFRs) are lipophilic substances with endocrine-disrupting properties. To
date, only few investigations, mainly retrospective case-control studies, have explored the link between internal
levels of BFRs and the risk of breast cancer, leading to conflicting results. We investigated the associations between
plasma concentrations of two main groups of BFRs, PBDEs (pentabromodiphenyl ethers) and PBBs (polybrominated
biphenyls), and the risk of breast cancer in a nested case-control study.
Methods: A total of 197 incident breast cancer cases and 197 controls with a blood sample collected in 1994–1999
were included. Plasma levels of PBDE congeners (BDE-28, BDE-47, BDE-99, BDE-100, BDE153, BDE-154) and of PBB-
153 were measured by gas chromatography coupled to high-resolution mass spectrometry. Conditional logistic
regression models, adjusted for potential confounders, were used to estimate odds ratios (ORs) and 95% confidence
intervals (CIs).
Results: Women were aged 56 years on average at blood draw. All cases, except for one, were diagnosed after
menopause, with an average age at diagnosis of 68 years. Overall, we found no evidence of an association between
plasma levels of PBDEs and PBB-153 and postmenopausal breast cancer risk (log-concentrations of BFRs yielding
non-statistically significant ORs of 0.87 to 1.07). The analysis showed a non-linear inverse association for BDE-100
and BDE-153 and postmenopausal breast cancer risk; nevertheless, these findings were statistically significant only
when the exposure was modeled as ng/L plasma (third vs. first quintile: OR = 0.42, 95%CI = 0.19–0.93 and OR = 0.42,
95%CI = 0.18–0.98, respectively) and not when modeled as ng/gr of lipids (OR = 0.58, 95%CI = 0.27–1.25 and OR =
0.53, 95%CI = 0.25–1.17). These results were unchanged in stratified analyses by tumor hormone receptor expression
or body mass index.
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Conclusions: Our results suggest no clear association between internal levels of PBDEs and PBB-153 and the risk of
breast cancer in postmenopausal women. However, these findings need to be carefully interpreted, taking into
account limitations due to the limited number of women included in the study, the lack of information concerning
genetic susceptibility of cases, and the unavailability of exposure assessment during critical windows of
susceptibility for breast cancer. More studies are warranted to further investigate the relationships between PBDE
and PBB exposure and breast cancer risk.
Keywords: Breast cancer, Brominated flame retardants (BFRs), Pentabromodiphenyl ethers (PBDEs), Polybrominated
biphenyls (PBBs), E3N cohort, Biomonitoring
Introduction
Despite a large body of research, the etiology of breast
cancer has not yet been fully delineated, as established risk
factors cannot solely explain the increased incidence re-
ported worldwide. In Europe, breast cancer is the most
common cancer in women with an incidence of 60 to 155
cases per 100,000 [1]. The main known risk factors for
breast cancer include non-modifiable risk factors - such as
age, early menarche, late menopause, family history of
breast cancer, and genetic mutations (e.g. mutations in the
BRCA1 and BRCA2 genes) - and modifiable risk factors -
such as use of hormonal treatments, alcohol consumption,
tobacco smoking, overweight, and lack of physical activity,
[2]. Nevertheless, it has been estimated that less than 25%
of breast cancers are attributable to the main modifiable
risk factors and between 10 and 30% to hereditary factors
[3, 4]. There is growing concern that exposure to chemical
environmental contaminants, particularly endocrine-
disrupting chemicals (EDCs), could be one of the factors
that led to an increased incidence of breast cancer in the
Western world [5].
Brominated flame retardants (BFRs) are lipophilic sub-
stances present as a mixture of congeners in several con-
sumer products to make them less flammable. Produced
since the early 1960s, their use has been progressively
limited and banned in Europe during the 90s when the
production reached the levels of 33,000 metric tonnes in
1994 [6]. PBBs were first restricted by the 4th amend-
ment to the marketing and use Directive 76/769/EEC
adopted in 1984 and in 2000 the production was volun-
tarily ceased by the industry [7]. Commercial mixtures
Penta- and Octa-PBDE products were first restricted in
1976 under the Directive 76/769/ECC and banned in
2003 in concentrations higher than 0.1% by mass [8].
Nevertheless, due to their resistance to degradation,
BFRs are widespread in the environment, even in areas
located remotely from sites of production or use [9].
Diet has been identified as the main source of exposure
to BFRs for adults, although the exposure can also be re-
lated to other routes such as inhalation or dermal ab-
sorption as a consequence of their accumulation in
indoor dust [10]. Unfortunately, the long-term toxic ef-
fects of these BFRs in humans are not completely
known, although they are suspected to act as EDCs,
since a link between exposure to BFRs and several
endocrine-related diseases has been reported [11]. In
2019, PBDEs, one of the major groups of BFRs, have
been included in the high-priority list of agents not pre-
viously evaluated by the International Agency for Re-
search on Cancer (IARC) Monographs on the basis of
relevant bioassay and mechanistic evidence [12].
There is increasing interest in understanding the con-
tribution of BFRs to breast cancer incidence; neverthe-
less, evidence of an association between environmental
exposure to these chemicals and breast cancer risk is still
inadequate to draw firm conclusions [5, 13]. To date,
only few studies have investigated the link between in-
ternal levels of BFRs and the risk of breast cancer, with
inconsistent results. To the best of our knowledge, re-
garding PBDE, all available studies followed a retrospect-
ive case control study design [14–17], while for PBB the
available studies were case-control studies nested in a
prospective cohort [18–20]. Finally, all the currently
available studies have been conducted in the US [14–16,
18–20] or in China [17], and none was performed in
Europe.
Our objective was to prospectively investigate the as-
sociations between plasma concentrations of two main
groups included in the family of BFRs, PBDEs and PBBs,
and the risk of postmenopausal breast cancer in women
in a case-control study nested in the French E3N cohort.
Methods
The E3N study
E3N (Etude Epidémiologique auprès de femmes de l’Edu-
cation Nationale) is a prospective cohort study involving
98,995 French women, aged 40–65 years at inclusion in
1990 and insured by a national health insurance cover-
ing workers from the French National Education System
(Mutuelle Générale de l’Education Nationale, MGEN)
[21]. Participants were enrolled after completing a base-
line self-administered questionnaire and returning a
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signed informed consent. Follow-up questionnaires were
sent every 2–3 years thereafter. Detailed cancer risk fac-
tor data were collected through questionnaires at differ-
ent time points during follow-up, including reproductive
history, use of hormonal treatments, anthropometric
characteristics, smoking habits, alcohol consumption,
diet, and physical activity. The average follow-up rate
per questionnaire cycle has been of 83%, and to date, the
total loss to follow-up since 1990 has been < 3%. The
study was approved by the French National Commission
for Data Protection and Privacy.
Between 1994 and 1999, E3N participants were invited
to donate blood, resulting in the collection of blood
samples from approximately 25,000 participants. Each
sample was separated into 28 aliquots (i.e. plasma,
serum, buffy-coat, leukocytes, and erythrocytes) that
were stored in plastic straws in liquid nitrogen con-
tainers (− 196 °C) in a biobank.
Breast cancer cases were identified through self-
report in the questionnaires, from the MGEN files, or
through information from death certificates. Deaths
were reported by family members and by searches in
the MGEN files, and causes of death were obtained
from the National Death Index. Pathology reports
were obtained for 93% of incident cases. We also
considered cases for which pathology reports have
not been obtained, because the proportion of false-
positive self-reports was low in our study population
(< 5%). Cases were identified up to 2013, which was
therefore used as the date of end of follow-up in stat-
istical analyses.
The nested case-control study on breast cancer
As previously described [22], 281 breast cancer cases for
which at least 3 aliquots of serum and 6 aliquots of
plasma were available in the biobank were identified
among the E3N population. From these, all cases who
had not completed the dietary questionnaire in 1993
(n = 27) or who were diagnosed before blood sampling
and/or before returning the dietary questionnaire were
excluded (n = 11). Cases of Paget’s disease and benign
breast disease were also excluded (n = 3). Finally, 240 in-
cident breast cancer cases were available. Due to budget
constraints, among those, 197 incident breast cancer
cases (174 invasive and 23 in situ) were randomly se-
lected and included in the study.
For each case, one control was sampled from women
who were free of breast cancer at the time of diagnosis
of the corresponding case (density sampling method).
Controls were matched to cases by age (±2 years), meno-
pausal status (premenopausal or postmenopausal), body
mass index (BMI) (< 25 or ≥ 25 kg/m2), all at blood col-
lection, and year of blood collection.
Measurement of biomarkers of exposure
The methodologies applied to isolate, detect, and quan-
tify the PBDE congeners (BDE-28, BDE-47, BDE-99,
BDE-100, BDE-153, BDE-154) and PBB-153 have been
published elsewhere [23, 24]. Briefly, plasma samples
were first submitted to a liquid/liquid extraction with
pentane. Resulting extracts were weighed to measure fat
content using an enzymatic method (Biolabo,Maizy,
France), and reconstituted in hexane for further purifica-
tion. The determinations were performed by gas chro-
matography (Agilent 7890A) coupled to high-resolution
mass spectrometry (GC-HRMS) on double sector instru-
ments (JEOL MS 700D and 800D) after electron impact
ionization (70 eV), operating at 10,000 resolutions (10%
valley) and in the single ion monitoring (SIM) acquisi-
tion mode. All the analyses have been conducted in an
ISO 17025:2005 accredited laboratory. The limits of de-
tection (LOD) were 0.03 ng/L for BDE-28, 0.02 ng/L for
BDE-154, and 0.1 ng/L for BDE-47, BDE-99, BDE-100,
BDE-153 and PBB-153. To ensure the quality of the ana-
lysis, besides the appropriate use of internal standards in
each sample, 13C12 labelled standards were added at the
end of each clean-up process in order to calculate recov-
eries that ranged between 60 and 120%. The accuracy
was determined according the ISO 17025 requirements,
setting up the lower spiking level at 0.5 ng/L (n = 5), be-
ing the trueness within the range between 3% (BDE-99)
and 37% (BDE-28), and the precision ranged between
13% (BDE-47) and 28% (PBB153). The analytical per-
formance was considered acceptable for all congeners;
however, it should be noted the analytical uncertainty
associated to lower concentrations for BDE28. Moreover,
cleaned laboratory glassware was rinsed with dichloro-
methane prior to use and the analyses were carried out
in an over-pressurized room to minimize environmental
contamination followed by a continuous monitoring of
the analytical procedure implemented through proced-
ural blanks [25]. The blank controls were not deducted
because of the absence of analytical contamination. The
accuracy of the analytical method was further ensured
by regular participation of the laboratory to proficiency
tests organized by the European Reference Laboratory
(EURL) for POPs. The total plasma lipid (TPL) levels
were calculated by using the Akins formula, combining
the concentration of phospholipids (PHO), triacylglycer-
ides (TAG), total cholesterol (t.CHO) and free choles-
terol (f.CHO) as follows: TPL = 1.677*(t.CHO-f.CHO) +
f.CHO + TAG+PHO) [26].
Statistical analysis
In all statistical analyses, values below the limit of detec-
tion (LOD) were substituted with the equivalent of
½LOD. Kruskal–Wallis tests were performed to compare
concentrations of PBDEs and PBB-153 between cases
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and controls. Spearman rank correlation tests were per-
formed to determine correlation structures between
plasma concentrations of PBDEs and PBB-153.
Conditional logistic regression models were used to es-
timate odds ratios (ORs) and 95% confidence intervals
(CIs) of breast cancer in relation to plasma concentra-
tion levels of PBDEs and PBB-153 expressed as ng/L
plasma. We also used conditional logistic regression
models using both the exposure variable as a continuous
variable, after log-transformation, and as a categorical
variable, dividing it into quintile groups based on plasma
concentrations of PBDEs and PBB-153 in controls.
When considering the exposure as a categorical variable,
tests for linear trend were performed by assigning the
median value to each quintile group and by modeling
these values as continuous variables. For all adjustment
variables, we considered the value collected in the last
questionnaire available before the date of diagnosis in
cases. All analyses were performed for each substance
separately and for the sum of concentrations of PBDEs.
An unadjusted model (Model 0) was fitted, as well as
three adjusted models with an increasing number of co-
variates. Model 1 was adjusted for total plasma lipid
content by the addition of a separate term in the model
(ng/L, continuous), as recommended by Schisterman
et al. [27]. Model 1 was further adjusted for smoking sta-
tus (never vs. ever), physical activity measured in meta-
bolic equivalent tasks (MET)-hour/week (< 35 vs. ≥35),
education (≤ 12 years, 12 to 14 years, > 14 years), per-
sonal history of benign breast disease (no vs. yes), and
family history of breast cancer (none, in first-degree rela-
tives, in extended relatives), parity and age at first full-
term pregnancy (FFTP) (no children, 1 or 2 children
and < 30 years old at FFTP, ≥3 children and < 30 years
old at FFTP, ≥ 30 years old at FFTP), total breastfeeding
duration (never, ≤6 or > 6 months), age at menarche (<
13 years vs. ≥ 13 years), current use of menopausal hor-
mone therapy (pre-menopausal, yes, no), use of oral con-
traceptives (ever vs. never), menopausal status and age
at menopause (pre-menopausal, menopause before age
51, menopause at age 51 or later). Finally, Model 2 was
further adjusted for adherence scores to the Healthy and
the Western dietary patterns (above vs. below the me-
dian), both derived using principal component analysis,
as previously described [28]. The selection of con-
founders was done a priori, based on the known breast
cancer risk factors available in our dataset that are po-
tentially associated with exposure to PBDEs and PBB-
153.
Using multinomial regression, stratified analyses were
performed based on tumor expression of estrogen (ER–
vs. ER+) and progesterone (PR– vs. PR+) receptors in-
cluding all variables used in Model 2. Since multinomial
regression models do not consider the case-control
matching, multinomial models were additionally ad-
justed for the matching criteria: age at blood draw (con-
tinuous), BMI at blood draw (continuous), and year of
blood draw (continuous), except for menopausal status
at blood draw, in order to avoid over-adjustment consid-
ering the a priori inclusion of age at menopause in the
model (premenopausal, postmenopausal and age at
menopause < 51 years, postmenopausal and age at
menopause ≥51 years). All subjects for whom the infor-
mation on hormone receptors was not available were
grouped as one “missing” category and inserted in the
model.
In order to better understand the underlying associ-
ation between lipids, BFRs and breast cancer, all analyses
were repeated using concentrations of PBDEs and PBB
expressed as ng/gr of lipids in the plasma.
Finally, the analyses were repeated excluding the case
diagnosed before menopause and her matched control.
Sensitivity analysis
Other authors highlighted that the evolution of body size
over lifetime may have an impact of the risk of develop-
ing breast cancer [29]. On the other hand, because of
the high lipophilicity of BFRs, it has been hypothesized
that changes in body weight prior to blood sampling
may partly explain circulating levels of BFRs, and that
their absorption, distribution, metabolism, and excretion
can be influenced by the evolution of body size [30]. In
order to test this, we built two additional models in a
sensitivity analysis. First, Model 2 was additionally ad-
justed for the evolution of women’s body size between
ages 8 and 35 years: the evolution trajectories of body
size were determined from the 8 somatotypes of Soren-
sen reported by the women at recruitment [31]. The
women reported which somatotypes best reflected their
body size at different periods in life (“around 8 years
old”, “at puberty”, “around 20-25 years old”, “around 30-
35 years old”). Using the PROC TRAJ of SAS 9.3, we
highlighted three trajectories of evolution of the body
size of each woman using age as time scale: normal body
size from ages 8 to 35 years; normal body size until pu-
berty, followed by a large body size afterwards; and large
body size from ages 8 to 35 years. All women were in-
cluded in these trajectories.
Then, Model 2 was adjusted for BMI variation over
the 5 years preceding blood sampling (BMI decrease of
more than 2 points; stable BMI; and BMI increase of
more than 2 points).
We conducted a stratified analysis based on BMI, con-
sidering groups with BMI < 25 and ≥25 kg/m2.
In our study population, missing values were < 5% for
all variables and were imputed to the median (continu-
ous variables) or modal value (categorical variables).
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Statistical analyses were performed using the SAS soft-
ware (version 9.4, SAS Institute). The threshold for stat-
istical significance was set at 5%. All statistical tests were
two-sided.
Results
The main characteristics of the study population are pre-
sented in Table 1.
Quantifiable levels of PBDE-47, 99, 100, 153, and PBB-
153 were detected in all samples. BDE-28 was detected
in all samples except for one control with a concentra-
tion below the LOD, while BDE-154 was below the LOD
in 99 samples (46 cases and 53 controls), representing
25% of the study population. The highest concentration
of BFR in the overall population was observed for BDE-
47 (median: 3.25 ng/L plasma; min-max: 0.39–82.65 ng/L
plasma), while the lowest was observed for BDE-154
(median: 0.16 ng/L plasma; min-max: 0.03–3.76 ng/L
plasma) (Table 2). Among PBDEs, we found high corre-
lations between BDE-47, 99, 100, and 154, while BDE-28
and BDE-153 had a more modest correlation with the
other congeners; in contrast, PBB-153 was very weakly
correlated with plasma levels of the PBDEs considered
in this study, except for PBDE-153 with which a stronger
correlation was observed (rho = 0.49) (Table 3).
Mean age at breast cancer diagnosis was 68.4 years
(range 54.3–84.9 years). All cases were diagnosed after
menopause except for one. Information on tumor hor-
mone receptor expression was available in 161 cases
(82%) for ER, and in 157 cases (80%) for PR. In total,
135 tumors were ER+ and 100 were PR+.
When considering concentrations of PBDEs and PBB
in ng/L plasma as continuous variables, we did not find
any statistically significant association between levels of
PBDEs and PBB-153 and breast cancer risk. When con-
sidering these concentrations modeled in quintiles, we
found no statistically significant association between the
sum of PBDEs, BDE-28, 47, 99, 154, or PBB-153 and
breast cancer risk in any of the models. In Models 1 and
2, women in the 3rd quintile group of BDE-100 were at
lower risk of breast cancer when compared with those in
the 1st quintile group (Model 2: OR 0.42, 95% CI 0.19–
0.93). Similarly, when considering BDE-153, we observed
a statistically significant inverse association with breast
cancer risk for women in the 3rd quintile group when
compared with those in the 1st quintile group in Models
1 and 2 (Model 2: OR 0.42, 95% CI 0.18–0.98) (Table 4).
After stratification based on hormone receptor status,
there was a statistically significant inverse association
only between the 3rd quintile group of BDE-153 and
ER+ breast cancer risk (OR 0.39, 95% CI 0.16–0.93) al-
though the number of cases included in the 3rd quintile
group was limited (e.g. 12 ER+ and 4 ER- cases) (Tables
S1 and S2).
When considering concentrations of PBDEs and PBB
in ng/gr of lipids in the plasma both as continuous vari-
ables and in quintiles, we did not find any statistically
significant association (Table 5). We also observed no
statistically significant association after stratifying based
on tumor expression of estrogen receptors, while we
found a positive association between the 3rd quintile
group of BDE-99 and PR- breast cancer risk (OR 3.13,
95%CI 1.03–9.54) and an inverse association between
women in the 2nd quintile group of PBB-153 and PR+
breast cancer risk (OR 0.34, 95% CI 0.14–0.83) (Tables
S3 and S4).
In a sensitivity analysis, we repeated the analyses after
excluding the case diagnosed before menopause and her
matched control, and the results remained unchanged
(data not shown). In addition, compared to the main
analyses, the results remained virtually unchanged in
terms of magnitude and statistical significance in sensi-
tivity analyses adjusting for the evolution of women’s
body size or BMI variation over the 5 years preceding
blood sampling (data not shown).
In analyses stratified according to BMI (< 25 and ≥25
kg/m2) and considering PBDE and PBB concentrations
in ng/L plasma, women in the 3rd quintile group of
BDE-100 with a BMI < 25 kg/m2 were at lower risk of
breast cancer (OR 0.33, 95% CI 0.12–0.90, compared
with the 1st quintile group). Among women with a BMI
≥25 kg/m2, we found an inverse association with breast
cancer risk among women in the 3rd quintile group of
BDE-153 (OR 0.05, 95% CI < 0.00–0.62) and among
those in the 3rd quintile group of PBB-153 (OR 0.13,
95% CI < 0.02–0.87). On the other hand, when consider-
ing concentrations of PBDEs and PBB in ng/gr of lipids
in the plasma, we observed a statistically significant in-
verse relationship only for the 2nd and 3rd quintile
groups of BDE-153 and only in women with a BMI ≥25
kg/m2 (OR 0.09, 95% CI 0.01–0.08 and OR 0.07, 95% CI
0.01–0.58, respectively) (Tables S5 and S6).
Discussion
In this nested case-control study of non-professionally
exposed French women, we found no evidence of an as-
sociation between plasma levels of PBDEs and PBB-153
and breast cancer risk, although when running the ana-
lyses with concentrations expressed as ng/L plasma,
there was an inverse association between the 3rd quintile
group of BDE-100 and BDE-153 and the risk of breast
cancer.
To date, few studies have investigated the association
between internal levels of PBDEs and PBB and breast
cancer risk, and they led to inconsistent results. One
study including 902 women with invasive breast cancer
and 936 controls from the California Teachers Study in-
vestigated the association between serum levels of BDE-
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Table 1 Distribution of selected characteristics for 394 study participants, E3N cohort
All Control Case
N(%) or Mean (STD) N(%) or Mean (STD) N(%) or Mean (STD)
All participants 394 (100) 197 (100) 197 (100)
Menopausal status and age at menopause at baseline
Pre-menopausal 78 (19.8) 39 (19.8) 39 (19.8)
Post-menopausal 316 (80.2) 158 (80.2) 158 (80.2)
Menopausal status and age at menopause at case’s date of diagnosis
Pre-menopausal 3 (0.8) 2 (1.0) 1 (0.5)
Post-menopausal 192 (48.7) 99 (50.3) 93 (47.2)
Age (years) at baseline 56.3 (6.2) 56.3 (6.2) 56.3 (6.2)
Age (years) at case’s date of diagnosis 68.4 (6.2) 68.4 (6.2) 68.4 (6.2)
BMI (kg/m2) at baseline
< 25 279 (70.8) 136 (69.0) 136 (69.0)
≥ 25 115 (29.2) 61 (31.0) 61 (31.0)
BMI (kg/m2) at case’s date of diagnosis
< 25 261 (66.2) 127 (64.5) 134 (68.0)
≥ 25 133 (33.8) 70 (35.5) 63 (32.0)
Total plasma lipid content (ng/L) 5.4 (0.8) 5.4 (0.9) 5.4 (0.8)
Smoking status at baseline
Never 192 (48.7) 90 (45.7) 102 (51.8)
Ever 202 (51.3) 107 (54.3) 95 (48.2)
Physical activity (metabolic equivalent tasks (MET)-hour/week) at baseline
< 35 202 (51.3) 100 (50.8) 102 (51.8)
≥ 35 192 (48.7) 97 (49.2) 95 (48.2)
Education level at baseline
< BAC 39 (9.9) 22 (11.2) 17 (8.6)
BAC to BAC + 2 192 (48.7) 98 (49.7) 94 (47.7)
≥ BAC + 2 163 (41.4) 77 (39.1) 86 (43.7)
Personal history of benign breast disease at baseline
No 250 (63.5) 135 (68.5) 115 (58.4)
Yes 144 (36.5) 62 (31.5) 82 (41.6)
Family history of breast cancer
None 281 (71.3) 146 (74.1) 135 (68.5)
In first-degree relatives 61 (15.5) 31 (15.7) 30 (15.2)
In extended relatives 52 (13.2) 20 (10.2) 32 (16.3)
Parity and age at first full-term pregnancy (FFTP)
No children 57 (14.5) 22 (11.2) 35 (17.8)
1 or 2 children and < 30 years old at FFTP 194 (49.2) 97 (49.2) 97 (49.2)
≥ 3 children and < 30 years old at FFTP 108 (27.4) 62 (31.5) 46 (23.4)
≥ 30 years old at FFTP 35 (8.9) 16 (8.1) 19 (9.6)
Total breastfeeding duration
Never 152 (38.6) 79 (40.1) 73 (37.1)
≤ 6 months 164 (41.6) 85 (43.1) 79 (40.1)
> 6 months 78 (19.8) 33 (16.8) 45 (22.8)
Age at menarche
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47, − 100, and − 153 and the risk of breast cancer, sug-
gesting no association [14].
A hospital-based study conducted among native Al-
askan women, including invasive and in situ breast can-
cer as cases (n = 75) and women with diagnoses of
benign breast conditions as controls (n = 95), failed to
find any statistically significant association between
serum levels of BDE-47 and breast cancer risk [15]. Two
studies have investigated the associations between levels
of PBDEs in breast adipose tissue and the risk of breast
cancer. The first one, a Californian hospital-based study,
which enrolled women with histologically-confirmed in-
vasive breast cancer as cases (n = 78) and women with
benign histological changes as controls (n = 56),
Table 1 Distribution of selected characteristics for 394 study participants, E3N cohort (Continued)
All Control Case
N(%) or Mean (STD) N(%) or Mean (STD) N(%) or Mean (STD)
< 13 years 178 (45.2) 95 (48.2) 83 (42.1)
≥ 13 years 216 (54.8) 102 (51.8) 114 (57.9)
Current use of menopausal hormone therapy at baseline
No 234 (59.7) 119 (60.7) 115 (58.7)
Yes 158 (40.1) 77 (39.1) 81 (41.1)
Use of oral contraceptives at baseline
Never 150 (38.1) 79 (40.1) 71 (36.0)
Ever 244 (61.9) 118 (59.9) 126 (64.0)
Adherence score to the Healthy dietary pattern
<median 197 (50.0) 89 (45.2) 108 (54.8)
> median 197 (50.0) 108 (54.8) 89 (45.2)
Adherence score to the Western dietary pattern
<median 197 (50.0) 98 (49.7) 99 (50.3)
> median 197 (50.0) 99 (50.3) 98 (49.7)
Table 2 Distribution of PBDE and PBB-153 levels (ng/L plasma and ng/gr lipids) in plasma samples collected among 394 study
participants between 1994 and 1999, E3N cohort
Cases Controls All *P
valuemean (sd) median (min-max) mean (sd) median (min-max) mean (sd) median (min-max)
PBDE sum (ng/L plasma) 10.66 (10.46) 8.43 (2.62–100.21) 11.06 (14.22) 8.37 (3.04–165.65) 10.86 (12.47) 8.4 (2.62–165.65) 0.67
PBDE sum (ng/gr lipids) 1.96 (1.73) 1.59 (0.42–17.38) 2.07 (2.75) 1.55 (0.57–31.02) 2.01 (2.29) 1.56 (0.42–31.02) 0.74
BDE-28 (ng/L plasma) 2.14 (4.07) 0.23 (0.03–2.99) 2.30 (4.80) 0.22 (0.03–3.9)** 2.20 (4.44) 0.22 (0.03–3.9) 0.49
BDE-28 (ng/gr lipids) 0.39 (0.79) 0.04 (0.01–0.71) 0.42 (0.79) 0.04 (0.01–0.73) 0.41 (0.79) 0.04 (0.01–0.73) 0.38
BDE-47 (ng/L plasma) 1.25 (1.29) 3.26 (0.39–63.95) 1.36 (1.80) 3.21 (0.85–82.65) 1.30 (1.56) 3.26 (0.39–82.65) 0.89
BDE-47 (ng/gr lipids) 0.23 (0.21) 0.63 (0.07–11.4) 0.25 (0.35) 0.60 (0.17–15.48) 0.24 (0.29) 0.62 (0.07–15.48) 0.92
BDE-99 (ng/L plasma) 3.15 (1.49) 0.73 (0.12–14.46) 3.13 (1.55) 0.74 (0.16–47.02) 3.14 (1.52) 0.74 (0.12–47.02) 0.35
BDE-99 (ng/gr lipids) 0.58 (0.25) 0.14 (0.02–2.54) 0.59 (0.31) 0.60 (0.17–15.48) 0.58 (0.28) 0.13 (0.02–8.81) 0.27
BDE-100 (ng/L plasma) 0.19 (0.15) 0.95 (0.13–12.28) 0.22 (0.32) 0.92 (0.23–15.85) 0.21 (0.25) 0.94 (0.13–15.85) 0.92
BDE-100 (ng/gr lipids) 0.04 (0.03) 0.17 (0.03–1.84) 0.04 (0.06) 0.18 (0.04–2.97) 0.04 (0.05) 0.18 (0.03–2.97) 0.87
BDE-153 (ng/L plasma) 0.33 (0.40) 2.84 (1.06–9.93) 0.33 (0.41) 2.84 (1.35–12.47) 0.33 (0.41) 2.84 (1.06–12.47) 0.85
BDE-153 (ng/gr lipids) 0.06 (0.08) 0.53 (0.22–1.76) 0.06 (0.08) 0.53 (0.22–2.34) 0.06 (0.08) 0.53 (0.22–2.34) 0.71
BDE-154 (ng/L plasma) 4.62 (6.64) 0.16 (0.02–1.16)** 4.76 (7.52) 0.15 (0.02–3.76)** 4.69 (7.09) 0.16 (0.02–3.76) 0.61
BDE-154 (ng/gr lipids) 0.84 (1.11) 0.03 (0–0.17) 0.89 (1.46) 0.03 (0–0.7) 0.86 (1.29) 0.03 (0–0.7) 0.52
PBB-153 (ng/L plasma) 1.12 (1.59) 1.59 (0.62–57.06) 1.27 (3.62) 1.66 (0.68–66.7) 1.20 (2.80) 1.64 (0.62–66.7) 0.76
PBB-153 (ng/gr lipids) 0.21 (0.27) 0.30 (0.12–11.12) 0.24 (0.69) 0.31 (0.11–10.94) 0.22 (0.53) 0.31 (0.11–11.12) 0.62
* Kruskal–Wallis test
** minimum value = limit of detection
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Table 4 Conditional logistic regression models to estimate the association between quintiles of PBDEs and PBB-153 plasma levels
expressed in ng/L and breast cancer risk: adjusted odds ratios (ORs) and 95% confidence intervals (CIs) (E3N cohort, N = 394)
ng/L plasma Model 0 P
trend
Model 1 P
trend
Model 2 P
trendNumber (%)
controls
Number (%) cases OR [95% CI] OR [95% CI] OR [95% CI]
PBDE sum 197 197
Q1 39(19.80) 37(18.78) Reference 0.97 Reference 0.66 Reference 0.59
Q2 39(19.80) 36(18.27) 0.99 [0.53; 1.84] 1.09 [0.52; 2.26] 1.14 [0.54; 2.41]
Q3 40(20.30) 38(19.29) 1.01 [0.56; 1.82] 1.00 [0.51; 1.94] 1.02 [0.52; 2.00]
Q4 39(19.80) 44 (22.34) 1.18 [0.64; 2.18] 1.20 [0.59; 2.44] 1.20 [0.59; 2.46]
Q5 40(20.30) 42 (21.32) 1.10 [0.58; 2.08] 1.13 [0.54; 2.39] 1.21 [0.57; 2.58]
log-PBDE sum 0.98 [0.67; 1.42] 0.9 0.95 [0.62; 1.46] 0.83 0.97 [0.63; 1.50] 0.88
BDE-28 197 197
Q1 39(19.80) 34 (17.26) Reference 0.32 Reference 0.47 Reference 0.54
Q2 39(19.80) 40 (20.30) 1.16 [0.62–2.18] 1.39 [0.67–2.90] 1.36 [0.65–2.85]
Q3 40(20.30) 34 (17.26) 0.99 [0.51–1.91] 0.92 [0.43–1.97] 0.99 [0.46–2.14]
Q4 39(19.80) 41 (20.81) 1.18 [0.62–2.26] 1.29 [0.61–2.72] 1.32 [0.63–2.80]
Q5 40(20.30) 48 (24.37) 1.36 [0.72–2.53] 1.33 [0.65–2.70] 1.27 [0.62–2.60]
log-BDE-28 1.04 [0.80; 1.37] 0.75 1.00 [0.74; 1.35] 0.98 0.97 [0.72; 1.33] 0.87
BDE-47 197 197
Q1 39(19.80) 41 (20.81) Reference 0.72 Reference 0.81 Reference 0.72
Q2 39(19.80) 34 (17.26) 0.82 [0.43–1.56] 0.71 [0.35–1.47] 0.73 [0.35–1.53]
Q3 40(20.30) 38 (19.29) 0.91 [0.50–1.67] 0.98 [0.49–1.95] 1.01 [0.50–2.05]
Q4 39(19.80) 40 (20.30) 0.97 [0.53–1.79] 0.84 [0.42–1.67] 0.83 [0.41–1.69]
Q5 40(20.30) 44 (22.34) 1.06 [0.57–1.95] 1.05 [0.52–2.11] 1.11 [0.54–2.26]
log-BDE-47 0.94 [0.70; 1.25] 0.66 0.92 [0.66; 1.29] 0.64 0.94 [0.67; 1.32] 0.72
BDE-99 197 197
Q1 39(19.80) 31 (15.74) Reference 0.55 Reference 0.66 Reference 0.66
Q2 39(19.80) 45 (22.84) 1.50 [0.77–2.90] 1.30 [0.62–2.73] 1.23 [0.57–2.62]
Q3 40(20.30) 38 (19.29) 1.27 [0.64–2.50] 1.26 [0.59–2.71] 1.32 [0.60–2.90]
Q4 39(19.80) 41 (20.81) 1.38 [0.70–2.72] 1.20 [0.56–2.56] 1.09 [0.50–2.38]
Q5 40(20.30) 42 (21.32) 1.36 [0.69–2.66] 1.28 [0.59–2.75] 1.29 [0.59–2.83]
log-BDE-99 1.04 [0.78; 1.39] 0.79 1.06 [0.76; 1.48] 0.72 1.07 [0.77; 1.49] 0.69
BDE-100 197 197
Q1 39(19.80) 49 (24.87) Reference 0.53 Reference 0.41 Reference 0.46
Q2 39(19.80) 36 (18.27) 0.71 [0.38–1.33] 0.56 [0.27–1.17] 0.59 [0.28–1.27]
Q3 40(20.30) 29 (14.72) 0.54 [0.28–1.05] 0.42 [0.19–0.92] 0.42 [0.19–0.93]
Q4 39(19.80) 46 (23.35) 0.93 [0.51–1.70] 0.91 [0.46–1.80] 0.87 [0.44–1.74]
Q5 40(20.30) 37 (18.78) 0.68 [0.35–1.30] 0.53 [0.24–1.17] 0.58 [0.26–1.28]
Log-BDE100 0.89 [0.65; 1.20] 0.44 0.95 [0.53; 1.70] 0.85 0.97 [0.54; 1.75] 0.91
BDE-153 197 197
Q1 39(19.80) 43 (21.83) Reference 0.92 Reference 0.73 Reference 0.78
Q2 39(19.80) 45 (22.84) 1.08 [0.58–2.01] 1.30 [0.63–2.68] 1.28 [0.62–2.67]
Q3 40(20.30) 22 (11.17) 0.52 [0.26–1.01] 0.40 [0.17–0.90] 0.42 [0.18–0.98]
Q4 39(19.80) 44 (22.34) 1.02 [0.56–1.87] 1.10 [0.55–2.22] 1.12 [0.55–2.29]
Q5 40(20.30) 43 (21.83) 0.96 [0.52–1.76] 0.85 [0.42–1.74] 0.87 [0.43–1.79]
log-BDE-153 1.02 [0.62; 1.68] 0.94 0.95 [0.53; 1.70] 0.85 0.97 [0.54; 1.75] 0.91
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provided no evidence of an association between adipose
tissue concentrations of BDE-47, − 99, − 100, − 153, and
− 154 and breast cancer risk [16]. The second was a
hospital-based study conducted in China (Shantou,
Chaoshan area) and included 209 cases and 165 con-
trols. In multivariable models adjusted for age and men-
archeal age, adipose tissue levels of BDE-47, − 71, − 99,
− 100, − 183 and − 209 were independently and positively
associated with breast-cancer risk [17]. Some major dif-
ferences need to be considered when comparing these
previous findings with our results. First, these studies
had a retrospective case-control design, implying that
the exposure level was measured at the time of diagnosis
(or after diagnosis), while in the present study blood
samples were drawn before breast cancer diagnosis.
Moreover, in the latter two studies, PBDE levels were
measured in adipose tissue, while in our study only
levels measured in blood were available.
Of note, a nested case-control study was conducted
based on 51 cases of breast cancer and 202 controls se-
lected among women residents in Michigan during the
industrial accident in 1973, which led to a high contam-
ination of the local food chain with PBB [18]. This study
found an OR of 2.60 (95% CI 0.93–7.27) for breast can-
cer incidence in women with a serum level of PBB ≥10
ng/mL compared with women with PBB ≤1 ng/mL. Al-
though not statistically significant, these results con-
firmed those found in two previous studies in the same
population that were performed within a shorter time
interval after the accident. Henderson et al. (follow-up
through 1992) and Hoque et al. (follow-up through
1993) found non-statistically significant positive associa-
tions between PBB exposure and breast cancer risk [19,
20]. These studies differed from ours in the fact that the
Michigan population represents a highly exposed group,
with circulating levels 1000-fold higher compared with
those found in our study population.
The exposure levels of PBDEs in our study were sub-
stantially lower compared to other previous studies with
a similar blood collection time. These diverging biomon-
itoring profiles are aligned with the higher production of
BFRs in US (e.g. 3–7 folds) in comparison to Europe be-
tween late 70s and 90s [6]. For instance, the median
concentration of BDE-153 was 6.5–7.2 ng/g in adipose
tissue from US [16] and 0.53 ng BDE-153 /g lipid of
plasma from France in the 90s (present study). These
lower levels of exposure in France are further supported
by subsequent studies conducted in US, finding a me-
dian of 4.8 ng/g lipid of serum between 2003 and 2004
[32], or in China, showing a range between 26.02–31.02
Table 4 Conditional logistic regression models to estimate the association between quintiles of PBDEs and PBB-153 plasma levels
expressed in ng/L and breast cancer risk: adjusted odds ratios (ORs) and 95% confidence intervals (CIs) (E3N cohort, N = 394)
(Continued)
ng/L plasma Model 0 P
trend
Model 1 P
trend
Model 2 P
trendNumber (%)
controls
Number (%) cases OR [95% CI] OR [95% CI] OR [95% CI]
BDE-154 197 197
Q1 39(19.80) 35 (17.77) Reference 0.47 Reference 0.86 Reference 0.86
Q2 39(19.80) 38 (19.29) 1.09 [0.56–2.11] 0.93 [0.44–1.97] 0.91 [0.43–1.96]
Q3 40(20.30) 38 (19.29) 1.08 [0.57–2.07] 1.04 [0.50–2.15] 1.06 [0.51–2.21]
Q4 39(19.80) 43 (21.83) 1.26 [0.66–2.43] 1.14 [0.54–2.41] 1.13 [0.53–2.40]
Q5 40(20.30) 43 (21.83) 1.24 [0.64–2.40] 1.00 [0.47–2.13] 1.00 [0.46–2.15]
log-BDE-154 0.99 [0.75; 1.31] 0.95 0.97 [0.70; 1.33] 0.83 0.96 [0.70; 1.33] 0.82
PBB-153 197 197
Q1 39(19.80) 47 (23.86) Reference 0.31 Reference 0.33 Reference 0.29
Q2 39(19.80) 41 (20.81) 0.90 [0.50–1.61] 0.73 [0.38–1.41] 0.67 [0.34–1.31]
Q3 40(20.30) 29 (14.72) 0.58 [0.31–1.11] 0.49 [0.23–1.07] 0.48 [0.22–1.06]
Q4 39(19.80) 51 (25.89) 1.06 [0.57–1.97] 0.96 [0.47–1.96] 0.92 [0.45–1.90]
Q5 40(20.30) 29 (14.72) 0.58 [0.29–1.13] 0.53 [0.24–1.17] 0.50 [0.22–1.13]
log-PBB-153 1.02 [0.62; 1.68] 0.94 0.95 [0.53; 1.70] 0.85 0.97 [0.54; 1.75] 0.91
Model 0: crude estimates;
Model 1: adjusted for total plasma lipid content (ng/L, continuous), smoking status (never vs. ever), physical activity measured in metabolic equivalent tasks (MET)-
hour/week (< 35 vs. ≥35), education (≤ 12 years, 12 to 14 years, > 14 years), personal history of benign breast disease (no vs. yes), and family history of breast
cancer (none, in first-degree relatives, in extended relatives), parity and age at first full-term pregnancy (FFTP) (no children, 1 or 2 children and < 30 years old at
FFTP, ≥3 children and < 30 years old at FFTP, ≥ 30 years old at FFTP), total breastfeeding duration (never, ≤6 or > 6months), age at menarche (< 13 years vs. ≥ 13
years), current use of menopausal hormone therapy (pre-menopausal, yes, no), and use of oral contraceptives (ever vs. never), menopausal status and age at
menopause (pre-menopausal, menopause before age 51, menopause at age 51 or later);
Model 2: Model 1 + adherence score to the Healthy and the Western dietary patterns (above vs. below the median)
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Table 5 Conditional logistic regression models to estimate the association between quintiles of PBDE and PBB-153 plasma levels
expressed as ng/gr of lipids and breast cancer risk: adjusted odds ratios (ORs) and 95% confidence intervals (CIs) (N = 394)
ng/gr lipids in the plasma Number (%)
controls
Number(%) cases Model 0
OR [95% CI]
P trend Model 1
OR [95% CI]
P trend Model 2
OR [95% CI]
P trend
PBDE sum 197 197
Q1 39(19.80) 44 (22.34) Reference 0,85 Reference 0.82 Reference 0.74
Q2 39(19.80) 29 (14.72) 0.68 [0.36–1.27] 0.56 [0.27–1.14] 0.63 [0.30–1.30]
Q3 40(20.30) 39(19.80) 0.90 [0.51–1.59] 0.92 [0.49–1.71] 0.90 [0.48–1.70]
Q4 39(19.80) 36(18.27) 0.82 [0.45–1.50] 0.77 [0.38–1.53] 0.85 [0.42–1.72]
Q5 40(20.30) 49 (24.87) 1.10 [0.60–2.01] 0.96 [0.48–1.91] 1.01 [0.50–2.01]
log-PBDE sum 197 197 0.99 [0.68–1.45] 0.98 0.95 [0.62–1.46] 0.81 0.96 [0.62–1.49] 0.86
BDE-28
Q1 39(19.80) 35 (17.77) Reference 0.36 Reference Reference 0.64
Q2 39(19.80) 39(19.80) 1.09 [0.58–2.02] 1.56 [0.76–3.20] 0.55 1.48 [0.71–3.09]
Q3 40(20.30) 33 (16.75) 0.91 [0.48–1.74] 0.87 [0.41–1.86] 0.91 [0.42–1.96]
Q4 39(19.80) 43 (21.83) 1.19 [0.65–2.17] 1.22 [0.61–2.45] 1.34 [0.67–2.71]
Q5 40(20.30) 47 (23.86) 1.27 [0.70–2.30] 1.28 [0.65–2.50] 1.19 [0.60–2.36]
log-BDE-28 1.05 [0.81–1.38] 0.7 0.99 [0.74–1.34] 0.9728 0.97 [0.71–1.33] 0.85
BDE-47 197 197
Q1 39(19.80) 41 (20.81) Reference 0.95 Reference 0.89 Reference 1,00
Q2 39(19.80) 36(18.27) 0.89 [0.49–1.61] 0.76 [0.39–1.47] 0.73 [0.37–1.44]
Q3 40(20.30) 37(18.78) 0.89 [0.49–1.62] 0.79 [0.40–1.53] 0.74 [0.37–1.46]
Q4 39(19.80) 43 (21.83) 1.04 [0.59–1.86] 0.97 [0.50–1.88] 0.98 [0.50–1.93]
Q5 40(20.30) 40(20.30) 0.95 [0.51–1.79] 0.89 [0.44–1.80] 0.93 [0.45–1.92]
log-BDE-47 0.95 [0.71–1.27] 0.71 0.92 [0.66–1.29] 0.6317 0.94 [0.66–1.32] 0.70
BDE-99 197 197
Q1 39(19.80) 32 (16.24) Reference 0.44 Reference 0.57 Reference 0.55
Q2 39(19.80) 38(19.29) 1.23 [0.63–2.41] 1.20 [0.58–2.49] 1.25 [0.59–2.64]
Q3 40(20.30) 40(20.30) 1.25 [0.64–2.44] 1.27 [0.61–2.64] 1.34 [0.64–2.84]
Q4 39(19.80) 46 (23.35) 1.47 [0.76–2.83] 1.24 [0.60–2.58] 1.20 [0.57–2.52]
Q5 40(20.30) 41 (20.81) 1.27 [0.66–2.44] 1.27 [0.61–2.67] 1.33 [0.63–2.81]
log-BDE-99 1.05 [0.79–1.41] 0.73 1.06 [0.76–1.47] 0.73 1.07 [0.76–1.49] 0.70
BDE-100 197 197
Q1 39(19.80) 43 (21.83) Reference 0.99 Reference 0.88 Reference 0.97
Q2 39(19.80) 41 (20.81) 0.97 [0.53–1.81] 0.85 [0.42–1.69] 0.99 [0.48–2.01]
Q3 40(20.30) 29 (14.72) 0.66 [0.35–1.27] 0.58 [0.27–1.24] 0.58 [0.27–1.25]
Q4 39(19.80) 40(20.30) 0.94 [0.52–1.72] 0.96 [0.48–1.91] 0.96 [0.48–1.93]
Q5 40(20.30) 44 (22.34) 1.01 [0.52–1.94] 0.87 [0.41–1.84] 0.99 [0.46–2.13]
log-BDE-100 0.90 [0.66–1.22] 0.48 0.86 [0.60–1.22] 0.40 0.87 [0.61–1.25] 0.46
BDE-153 197 197
Q1 39(19.80) 48 (24.37) Reference 0.85 Reference 0.84 Reference 0.87
Q2 39(19.80) 34 (17.26) 0.68 [0.36–1.30] 0.60 [0.28–1.27] 0.62 [0.29–1.31]
Q3 40(20.30) 29 (14.72) 0.57 [0.30–1.09] 0.52 [0.24–1.12] 0.53 [0.25–1.17]
Q4 39(19.80) 36(18.27) 0.69 [0.35–1.34] 0.75 [0.34–1.63] 0.83 [0.37–1.85]
Q5 40(20.30) 50 (25.38) 1.00 [0.56–1.80] 0.81 [0.41–1.61] 0.80 [0.40–1.61]
log-BDE-153 1.06 [0.64–1.76] 0.83 0.94 [0.52–1.68] 0.82 0.96 [0.53–1.73] 0.88
BDE-154 197 197
Mancini et al. Environmental Health           (2020) 19:54 Page 12 of 15
ng/g in adipose tissue between 2014 and 2016 [17],
whereas in France a median of 0.75 ng/ g lipid of serum
has been reported in the last biomonitoring study
(2014–2016) [33]. Moreover, our improved analytical
method substantially increased the sensitivity and the
number of detected samples, for instance, our mean
LOD for BDE153 was 0.1 ng/L whereas previous studies
have reported LOD of 17 ng/L [16].
Overall, we interpret the results from our study as null
findings. However, it should be noted that when running
the analyses with the exposure expressed as ng/L of
plasma, we observed a non-linear inverse association be-
tween levels of PBDE-100 and -153 and breast cancer
risk; nevertheless, this association was not statistically
significant when considering concentrations in ng/gr of
lipids in the plasma. With few exceptions, stratification
by tumor hormone receptor expression and BMI cat-
egories yielded similar results as the main analyses.
Therefore, given the relatively small number of cases
upon which these estimates are based, the inconsistency
in the results obtained for other PBDEs included in the
study, and the numerous statistical analyses that were
conducted, it is probable that these findings are due to
chance.
When interpreting these results, a limitation of our
study that should be taken into consideration is that
only a single measurement of PBDE and PBB-153
concentrations was available; we thus had no informa-
tion on the true trajectories of exposure or on exposure
levels during sensitive periods of breast development.
The present study was conducted with a population ex-
posed to low background levels of PBDEs and PBBs lim-
iting the conclusion to the low end of the population
dose-response curve. Moreover, previous studies have
suggested that certain genetic factors may modify the as-
sociations between exposure to EDCs and risk of breast
cancer [34], but no genetic information was available in
our study to investigate this hypothesis. Additionally,
PBDE and PBB-153 levels were measured in blood
plasma and no information on breast adipose tissue
levels of PBDEs and PBB-153 were available. Despite the
fact that blood biomarkers of lipophilic pollutants are
acknowledged to be good predictors of levels in adipose
tissue, many factors may affect the partition between
lipids from both compartments. For instance, the aver-
age partition adipose tissue:serum of PBDEs in lipid
basis was estimated around 0.5 for the congeners BDE-
28, − 47 and − 99 and between 0.8 and 1.1 for BDE-153,
− 154 and − 183 in Chinese women [35]. This imperfect
partition may hamper the interpretation of risk models
when using circulating biomarkers as proxies of adipose
tissue estimates, resulting, in some cases, in associations
in opposite directions [36]. Nonetheless, the systematic
comparison between models with lipid-adjusted and
Table 5 Conditional logistic regression models to estimate the association between quintiles of PBDE and PBB-153 plasma levels
expressed as ng/gr of lipids and breast cancer risk: adjusted odds ratios (ORs) and 95% confidence intervals (CIs) (N = 394)
(Continued)
ng/gr lipids in the plasma Number (%)
controls
Number(%) cases Model 0
OR [95% CI]
P trend Model 1
OR [95% CI]
P trend Model 2
OR [95% CI]
P trend
Q1 39(19.80) 33 (16.75) Reference 0.45 Reference 0.75 Reference 0.76
Q2 39(19.80) 38(19.29) 1.18 [0.61–2.28] 0.91 [0.43–1.92] 0.86 [0.40–1.85]
Q3 40(20.30) 41 (20.81) 1.26 [0.63–2.51] 1.30 [0.61–2.78] 1.35 [0.63–2.90]
Q4 39(19.80) 46 (23.35) 1.48 [0.74–2.97] 1.37 [0.63–2.98] 1.26 [0.58–2.77]
Q5 40(20.30) 39(19.80) 1.24 [0.63–2.44] 0.99 [0.46–2.11] 0.97 [0.45–2.10]
log-BDE-154 0.99 [0.75–1.32] 0.97 0.95 [0.69–1.31] 0.77 0.95 [0.69–1.32] 0.77
PBB-153 197 197
Q1 39(19.80) 37(18.78) Reference 0.59 Reference 0.80 Reference 0.74
Q2 39(19.80) 44 (22.34) 1.21 [0.63–2.32] 1.25 [0.60–2.61] 1.19 [0.56–2.56]
Q3 40(20.30) 41 (20.81) 1.12 [0.58–2.15] 1.09 [0.52–2.30] 1.05 [0.49–2.27]
Q4 39(19.80) 53 (26.90) 1.41 [0.73–2.72] 1.74 [0.81–3.75] 1.83 [0.83–4.04]
Q5 40(20.30) 22 (11.17) 0.62 [0.30–1.28] 0.61 [0.27–1.38] 0.52 [0.22–1.23]
log-PBB-153 1.06 [0.64–1.76] 0.83 0.94 [0.52–1.68] 0.83 0.96 [0.53–1.73] 0.88
Model 0: crude estimates;
Model 1: adjusted for smoking status (never vs. ever), physical activity measured in metabolic equivalent tasks (MET)-hour/week (< 35 vs. ≥35), education (≤ 12
years, 12 to 14 years, > 14 years), personal history of benign breast disease (no vs. yes), and family history of breast cancer (none, in first-degree relatives, in
extended relatives), parity and age at first full-term pregnancy (FFTP) (no children, 1 or 2 children and < 30 years old at FFTP, ≥3 children and < 30 years old at
FFTP, ≥ 30 years old at FFTP), total breastfeeding duration (never, ≤6 or > 6 months), age at menarche (< 13 years vs. ≥ 13 years), current use of menopausal
hormone therapy (pre-menopausal, yes, no), and use of oral contraceptives (ever vs. never), menopausal status and age at menopause (pre-menopausal,
menopause before age 51, menopause at age 51 or later);
Model 2: Model 1 + adherence score to the Healthy and the Western dietary patterns (above vs. below the median)
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wet-basis biomarkers did not yield substantial modifica-
tions of risk estimates, thus ruling out more complex
underlying associations. We used the parent forms of
PBDEs as biomarkers of internal exposure, while little is
known about the potential adverse health effects of their
hydroxylated forms as products of biotransformation
metabolism, which have shown exert estrogenic effects
[37]. Thus, one hypothesis to be deeper investigated for
explaining the observed reverse associations would be
the potential protective effect of adipose tissue by se-
questrating the parent compounds and more biologically
active hydroxylated metabolites, preventing the release
into circulation and thus the exposure of carcinogenic
cells [38]. Finally, we would also emphasize that, despite
the fact that the biomarkers were mostly detected in all
samples, we were not able to detect BDE-154 in 25% of
samples; thus, the related results should be considered
with caution due to the risk of bias associated to the
substitution of non-detected samples by ½ LOD.
Nevertheless, our study presents several strengths.
Thanks to the long follow-up duration of the E3N cohort,
we were able to prospectively investigate the long-term
health effects of plasma concentrations of PBDEs and PBB-
153. Extensive information on the main breast cancer risk
factors, such as reproductive history, use of hormonal treat-
ments, anthropometric characteristics, and lifestyle-related
risk factors, was collected prospectively in the cohort and
thus at the same time for cases and controls. Finally, the
availability of information on breast cancer expression of
estrogen and progesterone receptors allowed us to better
characterize the tumors and to perform stratified analyses.
Conclusion
Our results suggest no clear association between internal
levels of PBDEs and PBB-153 and risk of breast cancer in
postmenopausal women. Although our results are similar
to those found in previous research, they need to be care-
fully interpreted, taking into account study limitations due
to the limited number of women included in the study, the
lack of information concerning genetic susceptibility, and
the unavailability of exposure assessment during critical
windows of susceptibility for breast cancer. More studies
are warranted to further investigate the relationships be-
tween PBDE and PBB exposure and breast cancer risk, in
particular through deeper investigation related to the link
between those markers and lipids, and documenting expos-
ure levels for potentially active PBDE metabolites.
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